Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.

European urology - 1 Oct 2007

Shang Donghao, Ito Noriyuki, Watanabe Jun, Awakura Yasuo, Nishiyama Hiroyuki, Kamoto Toshiyuki, Ogawa Osamu

Abstract excerpt

OBJECTIVES: Immunochemical therapy combining cytokines and chemotherapeutic agents is expected to be effective for treating advanced renal cell carcinoma (RCC). We investigated the mechanism underlying the synergism of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) and the effect of p53 status on the synergy of the combined therapy in RCC cell lines. METHODS: The synergy of IFN-alpha and 5-FU was analyzed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Fluorouracil

Share to Gene Expression Regulation, Neoplastic

Share to Interferon-alpha

Share to Treatment Outcome

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 17275163
DOI: 10.1016/j.eururo.2007.01.045

Genes

PCNA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.PMID 17275163Read ↗

P53 reactivator PRIMA-1 MET synergizes with 5-Fluorouracil to induce apoptosis in pancreatic tumor cellsSemantic proximity Read ↗

Signaling through IFN Regulatory Factor-5 Sensitizes p53-Deficient Tumors to DNA Damage–Induced Apoptosis and Cell DeathSemantic proximity Read ↗

Interferonalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent pathway.Semantic proximity Read ↗

Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis.Semantic proximity Read ↗

Synergistic induction of apoptosis by acyclic retinoid and interferon-β in human hepatocellular carcinoma cellsSemantic proximity Read ↗

Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.Semantic proximity Read ↗

Potential of adenoviral p53 gene therapy and irradiation for the treatment of malignant gliomas.Semantic proximity Read ↗

Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo.Semantic proximity Read ↗

Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.Semantic proximity Read ↗

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.Semantic proximity Read ↗

Synergistic anti-tumor effects of nitroreductase mutants and p53.Semantic proximity Read ↗

p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.